Benjamin Oakes’ Scribe Therapeutics is developing specialized Crispr proteins to tackle a wide range of diseases–and it’s garnered deals with Big Pharma potentially worth over $4 billion.
This Scientist Is Building Custom Gene-Editing Tools—And Stands To Make Billions
Posted in biotech/medical, genetics